Nanosynth Group appoints Mark Duffin as new CEO

Nanosynth Group plc (LON:NNN) has announced the appointment of Mr. Mark Duffin as Chief Executive Officer of nanosynth, effective immediately.

Mr. Duffin is a qualified engineer with a multi-disciplinary background established over 20 years, including as CEO and board member of various companies in the technology, business services, industrial, manufacturing and consultancy sectors. His experience includes start-up companies, mergers and acquisitions and turnaround propositions.

Mr. Duffin is currently CEO and founder of Angel Share Capital Ltd and prior to that, was CEO of ServicePower Technologies plc (previously AIM listed) where he was responsible for executing a turnaround strategy for the company, resulting in a profit for the first time in fourteen years.  Mr. Duffin holds an MBA and a BEng Hons.

With this appointment, and as previously envisaged, Antony Legge will revert to his previous role of non-executive Chairman of the Company. Dr Cave’s move from a non-executive director to an executive director, taking the role of the Group’s Chief Scientific Officer, remains subject to contract and a further announcement will be made once finalised.  

Antony Legge, Chairman of nanosynth, said:

“I am delighted that a CEO of Mark’s calibre has agreed to join the Company.  His track record in creating shareholder value brings confidence that, together, we can continue to build nanosynth into a major player in the nanotech space.”

Mark Duffin, Chief Executive, said:

“I am excited to be joining the Board as CEO of nanosynth and am looking forward to working with Antony and the wider team as we work towards growing the Company for the benefit of our stakeholders.”

As part of his remuneration package Mr. Duffin will be granted share options over 5% of the Company’s current share capital in accordance with the Company’s EMI Share Scheme approved by shareholders at the Company’s recent Annual General Meeting.

These options vest on the third anniversary from grant and are exercisable up until the 7th anniversary of grant.

The options are exercisable in various tranches at prices varying from 1.00p to 4.00p and are subject to various additional conditions including the requirement for the Company’s 20 day volume weighted average share price to exceed the exercise price within certain timeframes. Further detail on the share options is set out below:

% of Issued Share CapitalNumber of OptionsExercise Price per OptionAdditionalVesting ConditionsExercise ConditionsExpiry Date
0.50%10,395,3601.00pNoneNone7 years from today
1.00%20,790,7201.25pThe 20 VWAP for the share price exceeding the Exercise Price at any time prior to 30 June 2022The option cannot be exercise in the 6 months following vesting7 years from today
2.50%51,976,8002.50pThe 20 VWAP for the share price exceeding the Exercise Price at any time prior to 30 June 2023The option cannot be exercise in the 6 months following vesting7 years from today
1.00%20,790,7204.00pThe 20 VWAP for the share price exceeding the Exercise Price at any time prior to 31 December 2023The option cannot be exercise in the 6 months following vesting7 years from today

The following information is disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies in relation to Mark Duffin, aged 54:

 Current directorships and/or partnerships:Former directorships and/or partnerships (within the last five years): 
Angel Share Capital Ltd
Angel Share Data Limited 
Clipeus Ltd
Sounding Board Ideas Ltd
V-Tech Renewables Ltd
Digital Breadcrumbs Ltd
Verde Tech Group Limited
Prime Advantage Investors Ltd
Prime Advantage Ltd
Upwind Shipping Holdings Ltd
Upwinds Shipping Holdings Ltd

There are no further disclosures required under Schedule 2(g) of the AIM Rules for Companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Nanosynth Group plc

    More articles like this

    Nanosynth Group plc

    Nanotechnology in cosmetics and cosmeceuticals

    Nanoparticles (NPs) are defined as materials with dimensions smaller than 100 nm and presenting various shapes, i.e., spheres, rods, dendritic shapes, etc. This definition is accepted by the European Union (EU) Commission. It should be noted, however,

    Nanosynth Group plc

    Nanoparticles in cosmetics

    Nanoparticles are particles that are smaller than 100 nanometer (1/10,000 millimeter) which is about 40,000 times thinner than a hair. There are two forms of nanoparticles: soluble and biodegradable nanoemulsions such as liposomes and insoluble nanopigments

    Nanosynth Group plc

    What nanoparticles do to our cells

    During the past few years, nanoparticles have been increasingly present in our everyday lives. To gain a better understanding of their health impacts, several studies have focused on the effects they have on our bodies and

    Nanosynth Group plc

    Role of nanotechnology for design and development of cosmeceutical

    Nanotechnology is an innovative area of science that includes the design, characterization, production, and application of materials, devices and systems by controlling shape and size at the nanometer scale (1–100 nm). Nanotechnology incorporation in cosmetic formulation

    Nanosynth Group plc

    Nanotech could be the next frontier of drug delivery

    Nanotechnology is an emerging and rapidly developing area in the pharmaceutical and medicinal field. For example, nanoparticles can be used as drug delivery systems. Nanotechnology could help overcome the limitations of conventional drug delivery such as biodistribution and

    Nanosynth Group plc

    Nanoparticles to aid cancer treatments

    Conventional therapies in cancer treatment face challenges in delivery of drugs in the body and just the quantity needed, due to the toxic nature of the medicines used that have unwanted side effects. Nanomaterials have ‘enormous’

    Nanosynth Group plc

    Nanoparticles: Emerging trends in human health and environment

    As part of the ongoing Govt of India initiative “Azadi ka Amrit Mahatosav”, the Indian Journal of Biochemistry and Biophysics (IJBB), CSIR-National Institute of Science Communication and Policy Research (NIScPR), New Delhi, has brought out its

    Nanosynth Group plc

    Nanoparticles that self-assemble inside cells to fight cancer

    Inspired by viral replication, researchers developed a therapy that commandeers biological processes to craft nanoparticles within macrophages to aid in cancer therapy. Through self-assembly, the nanoparticles address some of the delivery issues plaguing present renditions of nanomedicines,

    Nanosynth Group plc

    nanosynth Group getting a huge amount of traction (LON:NNN)

    nanosynth’s Mark Duffin discusses what the company does, the Volz trial results, joint venture with a global wellness company and what investors can expect for the rest of the year in this exclusive interview with DirectorsTalk.

    Nanosynth Group plc

    Nanotechnology in the nutricosmetics industry

    Nanotechnology for Nutricosmetics Nanocarriers are ubiquitous within nanomedicine; however, with skin quality and health in high demand for consumers, these fields have overlapped. The use of nanotechnology and nanoformulations as delivery systems for improving the performance

    Nanosynth Group plc

    Nanotechnology in cosmetics

    Nanotechnology is the science of manipulating atoms and molecules in the nanoscale – 80,000 times smaller than the width of a human hair. The world market for products that contain nanomaterials is expected to reach $2.6